US EditionLOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma
- On June 18, 2025, at the BIO International Convention in Boston, Lotte Biologics finalized a manufacturing deal with UK-based Ottimo Pharma to produce an antibody drug candidate.
- The deal followed Lotte Biologics' strategy to expand as a global CDMO amid growing demand for antibody therapeutics and ADC capabilities.
- Lotte Biologics will manufacture Jankistomig, a bispecific PD-1/VEGFR2 antibody targeting solid tumors, at their production facility located in Syracuse, New York.
- Lotte Biologics CEO James Park emphasized that the deal underscores the company's strong position in the global antibody drug CDMO sector, while Ottimo’s VP Joseph Shultz described the partnership as a key step forward in the development of Jankistomig.
- The contract boosts Lotte Biologics' CDMO position with production capacity increasing via its expanding Songdo Bio Campus, where Plant 1 will begin operating by 2027 with 120,000L bioreactor volume.
Insights by Ground AI
Does this summary seem wrong?
59 Articles
59 Articles
All
Left
4
Center
21
Right
4
LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma
Expanding track record by signing contracts with various global companies across Asia and Europe SEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced on June 19, 2025 that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a biopharmaceutical company developing first-in-class, one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer. The …
·New York, United States
Read Full Article
Lotte Biologics inks agreement with Ottimo Pharma on antibody drug candidate
BOSTON — Lotte Biologics signed a contract manufacturing agreement with U.K.-based biotech company Ottimo Pharma for its production of a novel antibody drug candidate known as Jankistomig, the Korean firm said on Wednesday.
·Seoul, Korea, Republic of
Read Full ArticleCoverage Details
Total News Sources59
Leaning Left4Leaning Right4Center21Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
